湖北广济药业股份有限公司关于取得甲钴胺片药品注册证书的公告

Core Viewpoint - Hubei Guangji Pharmaceutical Co., Ltd. has received the drug registration certificate for Mecobalamin Tablets from the National Medical Products Administration, marking a significant advancement in the company's product portfolio for the treatment of peripheral neuropathy [1][2][3]. Group 1: Basic Information - Drug Name: Mecobalamin Tablets [1] - Acceptance Number: CYHS2402791 [1] - Certificate Number: 2026S00402 [1] - Dosage Form: Tablet [1] - Packaging Specification: 10 tablets/board × 2 boards/box [1] - Registration Classification: Class 4 Chemical Drug [1] - Drug Registration Standard Number: YBH01362026 [1] - License Holder: Hubei Guangji Pharmaceutical Co., Ltd. [1] - Production Company: Hubei Guangji Pharmaceutical Co., Ltd. [1] - Approval Conclusion: The product meets the requirements for drug registration and has been approved for registration [1]. Group 2: Drug Application - Mecobalamin Tablets are primarily indicated for the treatment of peripheral neuropathy [2]. Group 3: Impact on the Company - The approval of the Mecobalamin Tablets registration certificate signifies an important development in the company's product layout for treating peripheral nerve diseases, providing high-quality domestic drug options for patients [3]. - The company aims to uphold the principle of "quality first, service health" and will fully promote the production and market supply of this product to benefit a wide range of patients [3].